PHARMOVO LTD

Executive Summary

PHARMOVO LTD demonstrates a high-risk profile due to stagnant minimal net assets, limited operational scale, and a sole director with potentially limited management experience. While regulatory filings are up to date and liabilities are absent, the absence of growth or trading activity raises concerns about the company’s sustainability. Further due diligence on revenue generation, business viability, and management capability is recommended before considering investment.

PHARMOVO LTD - Analysis Report

Company Number: 12542632

Analysis Date: 2025-07-20 15:47 UTC

1. Risk Rating: HIGH
   Justification: The company shows minimal financial activity with consistently nominal net assets (£1,000) over multiple years and no fixed assets or recorded liabilities. The lack of growth or operational scale, combined with a single employee and micro-entity status, indicates significant risk regarding sustainability and solvency.

2. Key Concerns:

   • Financial Stasis: Net assets have remained static at £1,000 for four consecutive years, with no evidence of revenue generation or asset accumulation.
   • Operational Scale: The company employs only one person (the director), indicating limited operational capacity and potential challenges in sustaining business activities.
   • Director Profile & Control: The sole director is a student with a significant ownership stake (50-75%) and voting rights, raising concerns about the professional management and governance experience necessary for business growth and compliance.

3. Positive Indicators:

   • Compliance: The company has filed accounts and confirmation statements on time with no overdue filings, indicating regulatory compliance.
   • No Liabilities: No current or long-term liabilities are reported, which minimizes immediate solvency pressures.
   • Clear Ownership Structure: The ownership and voting rights are well documented, showing transparency in control.

4. Due Diligence Notes:

   • Revenue and Profitability: Investigate whether the company generates any revenue or has any contracts, as financial statements lack any indication of trading activity.
   • Business Model Viability: Assess the viability of the AI pharmaceutical demand prediction service claimed on the website, including client base, pipeline, and technology readiness.
   • Director Competence & Background: Review the director’s experience, capacity to manage the business, and any potential conflicts or risks associated with a sole director who is a student.
   • Related Party Transactions: Examine if there are any transactions with related parties or external funding sources supporting the company.
   • Future Funding Plans: Explore whether there are plans for capital injection or business development to improve financial position.